ITZ-1

ITZ-1 is an orally active and selective extracellular signal-regulated kinase (ERK) -mitogen-activated protein kinase (MAPK) pathway inhibitor with an IC50 of 0.51 μM for inhibiting interleukin-1β (IL-1β) -induced matrix metalloproteinase-13 (MMP-13) production. ITZ-1 reduces MMP-13 expression and suppresses nitric oxide (NO) -induced chondrocyte apoptosi. ITZ-1 is promising for research of osteoarticular diseases[1].

Product Specifications

CAS Number

[1180532-17-5]

UNSPSC

12352005

Target

ERK; p38 MAPK

Related Pathways

MAPK/ERK Pathway; Stem Cell/Wnt

Field of Research

Inflammation/Immunology

Smiles

O=S(C1=CC=C(C)C=C1)(/N=C(C2=C(SCCCC(F)(F)C(F)(F)F)SC(C)=C(C)N23)\NC3=O)=O

Molecular Formula

C20H20F5N3O3S3

Molecular Weight

541.58

References & Citations

[1]Kimura H, et al. The chondroprotective agent ITZ-1 inhibits interleukin-1beta-induced matrix metalloproteinase-13 production and suppresses nitric oxide-induced chondrocyte death. J Pharmacol Sci. 2009 Jun;110 (2) :201-11.